Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
In a report released yesterday, Graham Parry from Bank of America Securities maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target of CHF110.00. Graham Parry has ...
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal ...
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...
Some results have been hidden because they may be inaccessible to you